Published in Oncogene on April 04, 2016
Protein-peptide molecular docking with large-scale conformational changes: the p53-MDM2 interaction. Sci Rep (2016) 0.75
Castanea sativa Mill. bark extract exhibits chemopreventive properties triggering extrinsic apoptotic pathway in Jurkat cells. BMC Complement Altern Med (2017) 0.75
Surfing the p53 network. Nature (2000) 35.36
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science (2004) 24.42
Mdm2 promotes the rapid degradation of p53. Nature (1997) 21.26
Regulation of p53 stability by Mdm2. Nature (1997) 18.20
Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature (1992) 17.40
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature (2007) 16.95
The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell (1992) 16.53
Cancer. p53, guardian of the genome. Nature (1992) 16.36
Participation of p53 protein in the cellular response to DNA damage. Cancer Res (1991) 16.00
Restoration of p53 function leads to tumour regression in vivo. Nature (2007) 12.62
The p53-mdm-2 autoregulatory feedback loop. Genes Dev (1993) 11.19
Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett (1997) 11.19
PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell (2001) 11.04
Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature (1995) 10.18
Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science (1996) 9.48
Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature (1991) 9.21
ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell (1998) 8.99
Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature (1995) 8.68
mdm2 expression is induced by wild type p53 activity. EMBO J (1993) 8.01
Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature (1993) 7.90
Emerging landscape of oncogenic signatures across human cancers. Nat Genet (2013) 6.48
A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci U S A (2001) 6.25
Modeling the therapeutic efficacy of p53 restoration in tumors. Cell (2006) 5.95
Regulation of HDM2 activity by the ribosomal protein L11. Cancer Cell (2003) 5.44
p53 mutations in cancer. Nat Cell Biol (2013) 5.18
p53 and metabolism. Nat Rev Cancer (2009) 5.05
Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway. Mol Cell Biol (2003) 4.61
Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat Genet (2001) 4.23
Gain of function mutations in p53. Nat Genet (1993) 4.19
MDMX: a novel p53-binding protein with some functional properties of MDM2. EMBO J (1996) 4.13
ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage. Genes Dev (2001) 4.06
Inhibition of MDM2-mediated p53 ubiquitination and degradation by ribosomal protein L5. J Biol Chem (2004) 4.05
MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer (2013) 3.60
The MDM2-p53 interaction. Mol Cancer Res (2003) 3.43
Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol (2012) 3.35
The ribosomal L5 protein is associated with mdm-2 and mdm-2-p53 complexes. Mol Cell Biol (1994) 3.16
The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol (2010) 3.08
MDM2 interacts with MDMX through their RING finger domains. FEBS Lett (1999) 2.98
Stabilization of the MDM2 oncoprotein by interaction with the structurally related MDMX protein. J Biol Chem (1999) 2.92
Drugging the p53 pathway: understanding the route to clinical efficacy. Nat Rev Drug Discov (2014) 2.88
Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase. Oncogene (2000) 2.84
HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53. Proc Natl Acad Sci U S A (2003) 2.73
Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res (1993) 2.65
MDM2 promotes ubiquitination and degradation of MDMX. Mol Cell Biol (2003) 2.45
PML regulates p53 stability by sequestering Mdm2 to the nucleolus. Nat Cell Biol (2004) 2.45
Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation. Cancer Cell (2007) 2.42
Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans. Cell Death Differ (2008) 2.36
Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell (2006) 2.32
ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage. EMBO J (2005) 2.29
The human MDM-2 oncogene is overexpressed in leukemias. Blood (1993) 2.24
Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy. Proc Natl Acad Sci U S A (2013) 2.22
The Mdm2 RING domain C-terminus is required for supramolecular assembly and ubiquitin ligase activity. EMBO J (2006) 2.21
MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin. J Biol Chem (2006) 2.20
Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. Proc Natl Acad Sci U S A (2006) 2.20
Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell (2005) 2.17
An essential function of the extreme C-terminus of MDM2 can be provided by MDMX. EMBO J (2006) 2.11
DNA damage-induced MDMX degradation is mediated by MDM2. J Biol Chem (2003) 2.03
Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. Cancer Res (2006) 2.03
Identification of a cryptic nucleolar-localization signal in MDM2. Nat Cell Biol (2000) 2.02
Phosphorylation of Hdmx mediates its Hdm2- and ATM-dependent degradation in response to DNA damage. Proc Natl Acad Sci U S A (2005) 1.97
Hdmx protein stability is regulated by the ubiquitin ligase activity of Mdm2. J Biol Chem (2003) 1.93
Hdmx modulates the outcome of p53 activation in human tumor cells. J Biol Chem (2006) 1.91
The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein. Cancer Biol Ther (2002) 1.91
Mdmx as an essential regulator of p53 activity. Biochem Biophys Res Commun (2005) 1.85
p53 in survival, death and metabolic health: a lifeguard with a licence to kill. Nat Rev Mol Cell Biol (2015) 1.84
Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development. Proc Natl Acad Sci U S A (2006) 1.82
Hdmx stabilizes Mdm2 and p53. J Biol Chem (2000) 1.81
MDMX regulation of p53 response to ribosomal stress. EMBO J (2006) 1.77
Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol (2012) 1.74
RING domain-mediated interaction is a requirement for MDM2's E3 ligase activity. Cancer Res (2007) 1.70
The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo. Proc Natl Acad Sci U S A (2011) 1.66
Solution structure of the Hdm2 C2H2C4 RING, a domain critical for ubiquitination of p53. J Mol Biol (2006) 1.61
MDM2 and MDM4: p53 regulators as targets in anticancer therapy. Int J Biochem Cell Biol (2007) 1.59
The contribution of the acidic domain of MDM2 to p53 and MDM2 stability. Oncogene (2001) 1.57
ATM activates p53 by regulating MDM2 oligomerization and E3 processivity. EMBO J (2009) 1.56
DNA damage induces MDMX nuclear translocation by p53-dependent and -independent mechanisms. Mol Cell Biol (2002) 1.53
Critical role for a central part of Mdm2 in the ubiquitylation of p53. Mol Cell Biol (2003) 1.51
Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during embryogenesis but dispensable for p53 and Mdm2 stability. Proc Natl Acad Sci U S A (2011) 1.51
Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells. Cell Death Dis (2011) 1.51
Expression of p53 during mouse embryogenesis. Development (1991) 1.50
Analysis of the degradation function of Mdm2. Cell Growth Differ (1999) 1.49
Critical contribution of the MDM2 acidic domain to p53 ubiquitination. Mol Cell Biol (2003) 1.49
Tyrosine phosphorylation of Mdm2 by c-Abl: implications for p53 regulation. EMBO J (2002) 1.45
Regulation of p53-MDMX interaction by casein kinase 1 alpha. Mol Cell Biol (2005) 1.41
Switching mechanisms of cell death in mdm2- and mdm4-null mice by deletion of p53 downstream targets. Cancer Res (2003) 1.32
MdmX protein is essential for Mdm2 protein-mediated p53 polyubiquitination. J Biol Chem (2011) 1.27
The RING domain of Mdm2 can inhibit cell proliferation. Cancer Res (2002) 1.26
Mdmx enhances p53 ubiquitination by altering the substrate preference of the Mdm2 ubiquitin ligase. FEBS Lett (2009) 1.24
MdmX is a RING finger ubiquitin ligase capable of synergistically enhancing Mdm2 ubiquitination. J Biol Chem (2002) 1.24
Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization. Proc Natl Acad Sci U S A (2012) 1.21
Functional role of Mdm2 phosphorylation by ATR in attenuation of p53 nuclear export. Oncogene (2003) 1.21
Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3. Oncogene (2011) 1.20
Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer. Oncogene (2002) 1.14
PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis. Oncogene (2005) 1.13
Validation of MdmX as a therapeutic target for reactivating p53 in tumors. Genes Dev (2011) 1.11
MDM2 and MDMX can interact differently with ARF and members of the p53 family. FEBS Lett (2001) 1.10
Protein kinase CK1delta phosphorylates key sites in the acidic domain of murine double-minute clone 2 protein (MDM2) that regulate p53 turnover. Biochemistry (2004) 1.09
c-Abl phosphorylates Hdmx and regulates its interaction with p53. J Biol Chem (2008) 1.09
N-terminal 130 amino acids of MDM2 are sufficient to inhibit p53-mediated transcriptional activation. Oncogene (1995) 1.08